AGP Executive Report
Last update: 3 hours agoIn-Body Gene Editing: Prime Medicine has treated its first Wilson’s disease patient with prime editing delivered directly into the body. The trial will test whether it can safely correct the faulty gene; initial results are expected in 2027. New Treatments: The FDA granted accelerated approval to Voceryq, the first plasmid DNA immunotherapy, for recurrent respiratory papillomatosis. Separately, a trial of nasal-spray mebufotenin found reduced depression symptoms lasting through eight weeks. AI Drug Discovery: Parse Biosciences and Nomic Bio plan a 100-million-cell dataset linking immune-cell gene activity to proteins released by cells, with major drugmakers among the partners. Semiconductors: India’s chip ambitions face a supply-chain gap: the country still imports most semiconductor-grade materials, chemicals, equipment and critical minerals, industry experts say. Planetary Science: A decade of Juno observations has exposed a mismatch between Jupiter’s measured interior and the Galileo probe’s atmospheric readings, challenging how scientists study giant planets.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
